In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including proteins, oligonucleotides, viral vectors, and engineered cells. One area within Complex Biologics experiencing tremendous growth is oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range of diseases.

Certara supported the first FDA approval of an oligonucleotide therapy as well as 23 subsequent programs. Watch this video to learn more about oligonucleotide therapeutics, and how they work.

Please visit us at https://www.certara.com/oligonucleoti... to learn more.